The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. PhRMA is committed to advancing public policies in the United States and around the world that support innovative medical research, yield progress for patients today and provide hope for the treatments and cures of tomorrow.
PhRMA maintains a database of clinical trials organized by state. Biopharmaceutical research and clinical trials are taking place across the U.S. every day. You can explore clinical trial data by use of an interactive map. The information includes data on biopharmaceutical jobs, the industry’s overall economic impact, clinical trial activity, and more.
PhRMA Solutions
Encourage Use of 21st Century Tools for Drug Evaluation
Review and ApprovalScientific advances are re-shaping our understanding of the causes of disease, creating new avenues of research, exploration and discovery. New and powerful tools emphasize individual patient characteristics and include innovative clinical trial design, advanced statistical methods and use of real-world evidence.
Ensure FDA Drug Approval Is Scientifically Sound and Efficient
Medical and basic science is advancing at a breathtaking rate. New developments – including those in immunologic and cell therapies, personalized medicine and regenerative medicine – hold the promise of treating debilitating diseases such as Alzheimer’s, cancer, diabetes and many rare disorders.
Reduce the Generic Backlog and Incentivize Competition Where Needed
A generic drug enters the market at the end of an innovative medication’s lifecycle. When it does, the FDA allows the manufacturer to submit an Abbreviated New Drug Application (ANDA), which does not require repetition of time consuming and costly clinical trials the innovative biopharmaceutical company conducted. As a result, generics can enter the market at a fraction of the price of an innovator medicine. With nearly 90 percent of all U.S. retail prescriptions filled with generics, their timely approval is critical to patient access and the long-term sustainability of our health care system.
